| Metastatic Castration-Sensitive Prostate Carcinoma
Erleada vs Nubeqa
Side-by-side clinical, coverage, and cost comparison for metastatic castration-sensitive prostate carcinoma.Deep comparison between: Erleada vs Nubeqa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNubeqa has a higher rate of injection site reactions vs Erleada based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nubeqa but not Erleada, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Erleada
Nubeqa
At A Glance
Oral
Once daily
Androgen receptor inhibitor
Oral
Twice daily
Androgen receptor inhibitor
Indications
- Metastatic Castration-Sensitive Prostate Carcinoma
- Nonmetastatic Castration-Resistant Prostate Carcinoma
- Hormone refractory prostate cancer
- Metastatic Castration-Sensitive Prostate Carcinoma
Dosing
Metastatic Castration-Sensitive Prostate Carcinoma, Nonmetastatic Castration-Resistant Prostate Carcinoma 240 mg orally once daily with or without food; concurrent GnRH analog or prior bilateral orchiectomy required; reduce to 120 mg once daily in severe hepatic impairment (Child-Pugh C).
Hormone refractory prostate cancer 600 mg (two 300 mg tablets) orally twice daily with food; continue until disease progression or unacceptable toxicity.
Metastatic Castration-Sensitive Prostate Carcinoma 600 mg (two 300 mg tablets) orally twice daily with food; when used with docetaxel for mCSPC, administer first of 6 cycles of docetaxel within 6 weeks of starting NUBEQA; continue NUBEQA until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) fatigue, arthralgia, rash, decreased appetite, fall, weight decreased, hypertension, hot flush, diarrhea, fracture
Serious cerebrovascular and ischemic cardiovascular events, fracture, ILD/pneumonitis, severe cutaneous adverse reactions (SCARs)
Postmarketing ILD/pneumonitis, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), DRESS, lichenoid eruption
Most common (>=10%) Increased AST, decreased neutrophil count, increased bilirubin, fatigue, increased ALT (nmCRPC and mCSPC); constipation, rash, decreased appetite, hemorrhage, increased weight, hypertension (mCSPC with docetaxel).
Serious Febrile neutropenia (6%), decreased neutrophil count (2.8%), musculoskeletal pain (2.6%), pneumonia (2.6%), urinary retention, hematuria, arrhythmias, spinal cord compression, ischemic heart disease, heart failure.
Postmarketing COVID-19/COVID-19 pneumonia, myocardial infarction, sudden death, seizures, drug-induced liver injury.
Pharmacology
Androgen receptor (AR) inhibitor; apalutamide binds directly to the ligand-binding domain of the AR, inhibiting nuclear translocation, DNA binding, and AR-mediated transcription, leading to decreased tumor cell proliferation and increased apoptosis in prostate cancer models.
Darolutamide is an androgen receptor (AR) inhibitor that competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. The major metabolite ketodarolutamide exhibits similar in vitro activity and decreased prostate cancer cell proliferation in vitro and tumor volume in xenograft models.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Erleada
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Nubeqa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Erleada
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Nubeqa
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Erleada
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Nubeqa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ErleadaView full Erleada profile
NubeqaView full Nubeqa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.